210 papers
Immunology explores the intricate defense systems that keep our bodies safe from infections and disease. This field examines how our immune cells recognize threats, coordinate responses, and maintain a delicate balance between fighting invaders and avoiding self-harm. From understanding vaccine mechanisms to investigating autoimmune disorders, these studies reveal the dynamic biology protecting human health every day.
On Gist.Science, we ensure these critical discoveries remain accessible to everyone. We automatically process every new preprint in this category as it appears on bioRxiv, transforming complex research into both plain-language explanations and detailed technical summaries. This approach allows readers to grasp the core findings without getting lost in dense jargon, while still providing the depth needed for scientific inquiry.
Below are the latest immunology papers from bioRxiv, each accompanied by our curated summaries to help you navigate the newest breakthroughs in the field.
This study demonstrates that agarikon mycelium exerts a context-dependent, adaptive immune-modulating effect in human cells by selectively engaging innate immune pathways under basal conditions while buffering oxidative stress and preventing cytokine overstimulation during LPS-induced inflammation.
This study identifies novel HLA-A33-restricted CD8+ T cell epitopes from avian influenza A/H5N1, revealing allotype-specific presentation differences and demonstrating that conserved peptides can elicit cross-reactive immunity in HLA-A*33:03-positive individuals, thereby offering promising candidates for the development of broadly protective vaccines.
This study demonstrates that fractionated irradiation enhances the efficacy of adoptive T cell therapy in malignant gliomas by reprogramming tumor endothelial cells to upregulate adhesion molecules and antigen presentation, thereby facilitating the infiltration, expansion, and activation of tumor-specific cytotoxic T cells.
This study presents a novel therapeutic strategy for rheumatoid arthritis using synovium-restricted, armored CAR-T cells that target PD-1-expressing pathogenic T cells while secreting sTNFRII to modulate the inflammatory microenvironment and resolve experimental arthritis.
This study demonstrates that the RIG-I/MDA5-MAVS-IRF3 axis senses Tonate virus infection to activate the type I interferon pathway, which is essential for restricting viral replication in human cells.
By applying host-pathogen spatial transcriptomics to over 23 million cells from Cystic Fibrosis and COPD lungs, this study reveals that chronic *Pseudomonas aeruginosa* infection persists as a spatially partitioned ecosystem where distinct anatomical niches drive specific bacterial lifestyles and host inflammatory responses, suggesting that effective eradication therapies must target these diverse microenvironments.
This study reveals that rare CD56dimCD16dim NK cells, characterized by high NKG2D expression and enhanced ADAM17-mediated CD16 turnover, are the dominant effectors against HIV-infected T-cells through superior direct cytotoxicity and ADCC, offering a critical target for HIV therapies.
This study demonstrates that encapsulating the STING-activating molecule cGAMP within bacteriophage MS2 virus-like particles significantly enhances its stability and cellular delivery, resulting in a highly potent, STING-dependent antitumor immune response in vivo at concentrations 50-fold lower than free or synthetic analogs.
This study utilizes single-cell RNA sequencing to reveal that acute Chikungunya virus infection triggers a potent, monocyte-driven systemic interferon response and distinct adaptive immune alterations, characterized by plasmablast differentiation and T-cell exhaustion, which are more intense than those observed in Dengue virus infections.
This study reveals that antibiotics increase susceptibility to *C. difficile* infection not only by disrupting the gut microbiome but also by driving a CCR5-dependent immune imbalance characterized by the expansion of pathogenic CCR5+ immune cells, which can be mitigated by targeting the CCL3/4/5-CCR5 signaling pathway.